Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ResApp Health : Agreement secured with Ilara Health to sell ResAppDx in Kenya

05/03/2021 | 07:13pm EDT

View printer-friendly version

  • Ilara Health appointed to promote, market and sell ResAppDx in Kenya
  • Ilara provides access to a large potential customer base in Kenya and has established partnerships with over 250 primary care clinics across the country
  • Agreement follows an initial pilot evaluation of ResAppDx undertaken by Ilara at five partner sites across Kenya

Brisbane, Australia, 4 May 2021 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that health technology company Ilara Health ('Ilara') will promote, market and sell ResAppDx, ResApp's smartphone app for acute respiratory disease diagnosis, in Kenya. The non-exclusive distribution agreement follows a successful pilot evaluation undertaken by Ilara of ResAppDx at five partner sites across Kenya (refer ASX announcement: 30 June 2020).

Ilara Health powers existing primary care facilities with next-generation point of care diagnostic tools to bridge the diagnostic gap across sub-Saharan Africa. Ilara are currently partnered with over 250 clinics across the four largest cities in Kenya and will look to expand across the wider country and a new African market within the next 12 months.

ResAppDx is ResApp's acute respiratory diagnostic test that uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone's inbuilt microphone. It is CE Marked in Europe and TGA approved for ARTG (Australian Register of Therapeutic Goods) listing in Australia. ResAppDx is also approved as a medical device in Kenya.

Over 500m people in Africa struggle to access high quality healthcare. Many doctors across the continent have a limited ability to perform diagnostics in their clinic. According to the WHO, lower respiratory tract infections are the leading cause of death in Africa, resulting in nearly a million deaths in 2016.

CEO and Co-founder of Ilara Health Emilian Popa said: 'We have been thrilled with the simplicity, ease of use and confidence that ResAppDx has instilled in clinicians and patients. We see significant benefits that ResAppDx offers our partner clinics across Kenya as a low-cost and accurate respiratory diagnostic test.'

'ResApp's smartphone-based technology is an ideal fit for our clients and our technology platform, which aims to lower the cost of diagnostics and make them accessible and affordable to the 500 million people in Africa that struggle to access a high level of healthcare.'

CEO and Managing Director of ResApp, Dr Tony Keating said: 'We are pleased that Ilara has seen the considerable value that our important diagnostic support provides their customers. Importantly, the pilot evaluation demonstrated the benefits of ResAppDx in a face-to-face, in-clinic setting and in a country with high unmet need for such diagnostics. We are confident, that with the learnings from this pilot, Ilara Health will be able to bring the value of ResAppDx to a broad range of clinics in Kenya for the benefit of many clinicians and patients.'

The non-exclusive distribution agreement has an initial term of three years and appoints Ilara to promote and sell ResAppDx in Kenya. Following the initial term, the agreement may be renewed for successive 12-month periods on mutual agreement. Either party may terminate the agreement by providing 90 days notice.


About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

About Ilara Health
Ilara Health is a Kenya-based health technology company addressing the lack of accessible and accurate diagnostics across sub-Saharan Africa. Ilara Health partners with next generation point of care, regulatory-approved medical device manufacturers that use new technologies to achieve substantial cost reductions in equipment for primary care clinics. Since its inception in 2019, Ilara Health has worked with 250+ small to medium-sized Kenyan clinics and medical centres, providing these facilities with access to novel diagnostics tools and to Ilara Health's technology platform. Through Ilara Health's smart financing options, primary care facilities can now offer previously inaccessible, life-saving tests, improving the quality of care they are able to provide to their communities. The long-term mission is to make basic diagnostics affordable and accessible to the 500m people across Africa who struggle to access even a simple blood test. For more information, please visit www.ilarahealth.com.


ResApp Health Limited published this content on 04 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 May 2021 23:12:08 UTC.

ę Publicnow 2021
09/19RESAPP HEALTH : Recruits First Patients in India in COVID-19-Related Cough Sounds Study
09/19RESAPP HEALTH : First patients recruited in COVID-19 clinical study in India
09/14RESAPP HEALTH : Gets Regulatory Nod for R&D Rebate; Shares Fall 6%
09/13RESAPP HEALTH : receives Advanced and Overseas R&D finding
09/13ResApp Health Limited Receives Advanced and Overseas R&D Finding
09/01RESAPP HEALTH : Secures Indonesian Regulatory Approval for Diagnostic App
08/31RESAPP HEALTH : ResAppDx receives regulatory approval in Indonesia
08/31ResApp Health Limited Receives Regulatory Approval in Indonesia
08/26ResApp Health Limited Reports Earnings Results for the Full Year Ended June 30, 2021
08/26ResApp Health Limited Auditor Raises 'Going Concern' Doubt
More news
Sales 2021 0,07  0,05  0,05 
Net income 2021 -6,77 M -4,91 M -4,91 M
Net cash 2021 6,40 M 4,64 M 4,64 M
P/E ratio 2021 -4,71x
Yield 2021 -
Capitalization 68,7 M 49,7 M 49,8 M
EV / Sales 2020 -
EV / Sales 2021 413 455 192x
Nbr of Employees 500
Free-Float 84,4%
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Al Rey Lunar Vice President-Finance
Roger Aston Non-Executive Chairman
Christopher Ntoumenopoulos Non-Executive Director
Brian Leedman Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SNAP INC.51.97%121 047
ANGI INC.-10.04%5 985
GRUBHUB INC.-19.36%5 591
PERFECT WORLD CO., LTD.-46.95%4 846